Invesaro

Stocks XRTX Financial statements

Financial statements

XORTX Therapeutics Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data XORTX Therapeutics Inc. files with the SEC in its annual reports.

In CAD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2019FY2021FY2021
Research and development0.040.280.85
General and administrative0
Pre-tax income-0.57-1.4-3.65
Net income-0.63-1.28-1.65

Balance sheet

FY2019FY2021FY2021
Cash and equivalents0.060.1718.9
Total current assets2.0620.2
Total assets2.2922
Total current liabilities1.030.7
Total liabilities1.035.3
Retained earnings-8.04-9.69
Shareholders' equity1.2616.7
Total equity-0.211.2616.7
Total liabilities and equity2.2922

Cash flow statement

FY2019FY2021FY2021
Net income-0.63-1.28-1.65
Depreciation and amortization0.020.020.02
Cash from operations-0.25-0.73-6.06
Cash from financing0.060.8624.5
Exchange rate effect0.33
Net change in cash-0.20.1118.7

Key metrics

Worked out from the statements above. Latest values use fiscal 2021. No valuation: the share price is quoted in a different currency than the statements.

Profitability

MetricValueHow it is calculated
Return on equity (ROE)-18.4%Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)-13.6%Net income / average total assets.

Growth

MetricValueHow it is calculated
Book value growth, 1y1,232.0%Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y862.1%Total assets vs the same period a year earlier. Only from a positive base.

Balance sheet health

MetricValueHow it is calculated
Current ratio28.8xCurrent assets / current liabilities.
Quick ratio26.9x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio26.9x(Cash + short-term investments) / current liabilities.
Liabilities / assets24.0%Total liabilities / total assets.
Working capitalCA$19.5MCurrent assets - current liabilities.
Tangible book valueCA$16.7MShareholders' equity - goodwill - intangible assets.
Was XORTX Therapeutics Inc. profitable in fiscal 2021?

No. It reported a net loss of CA$1.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to XORTX Therapeutics Inc.